Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary.

Goodwin GM. et al, (2024), Am J Psychiatry, 181, 79 - 81

Combining antidepressants and attention bias modification in primary health care (DEPTREAT): Protocol for a pragmatic randomized controlled trial.

Landrø NI. et al, (2023), Contemp Clin Trials, 133

The psychedelic experience and treatment-resistant depression.

Goodwin GM., (2023), World Psychiatry, 22, 420 - 422

Reducing intrusive memories after trauma via an imagery-competing task intervention in COVID-19 intensive care staff: a randomised controlled trial.

Iyadurai L. et al, (2023), Transl Psychiatry, 13

Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.

Dougherty RF. et al, (2023), Psychopharmacology (Berl)

A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression.

Jauhar S. et al, (2023), Mol Psychiatry, 28, 3149 - 3152

The IBER study: a feasibility randomised controlled trial of imagery based emotion regulation for the treatment of anxiety in bipolar disorder.

Steel C. et al, (2023), Int J Bipolar Disord, 11

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Goodwin GM. et al, (2023), Neuropsychopharmacology

Must Psilocybin Always "Assist Psychotherapy"?

Goodwin GM. et al, (2023), Am J Psychiatry

Psilocybin for Treatment-Resistant Depression. Reply.

Goodwin GM. et al, (2023), N Engl J Med, 388

Unblinding and demand characteristics in the treatment of depression.

Goodwin GM. et al, (2023), J Affect Disord, 328, 1 - 5

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.

Goodwin GM. et al, (2023), J Affect Disord

Excess resource use and costs of physical comorbidities in individuals with mental health disorders: A systematic literature review and meta-analysis.

Simon J. et al, (2023), Eur Neuropsychopharmacol, 66, 14 - 27

Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.

Joas E. et al, (2022), Pharmacogenomics J

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

Goodwin GM. et al, (2022), N Engl J Med, 387, 1637 - 1648

Using a generative model of affect to characterize affective variability and its response to treatment in bipolar disorder.

Pulcu E. et al, (2022), Proc Natl Acad Sci U S A, 119

Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs.

Similon MVM. et al, (2022), Eur Neuropsychopharmacol, 60, 91 - 99

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice.

Thomas CW. et al, (2022), Transl Psychiatry, 12

Identifying psychiatric diagnosis from missing mood data through the use of log-signature features.

Wu Y. et al, (2022), PLoS One, 17

The costs of bipolar disorder in the United Kingdom.

Simon J. et al, (2021), Brain Behav, 11

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?